Skip to content

Effect of Peritoneal Fixation on Lymphocele Formation

Prospective Randomized Trial Evaluating the Effect of Peritoneal Flap Fixation on Symptomatic and Radiologic Lymphocele Formation Following Robot Assisted Radical Prostatectomy With Extended Pelvic Lymph Node Dissection (PerFix)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04853095
Acronym
PerFix
Enrollment
260
Registered
2021-04-21
Start date
2019-12-01
Completion date
2022-01-01
Last updated
2022-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphocele After Surgical Procedure, Prostate Cancer

Keywords

Prostate cancer, Robot-assisted radical prostatectomy, Extended pelvic lymph node dissection, Lymphocele, Peritoneal fixation, Lymphatic disease

Brief summary

The PerFix Trial aims to compare the use of peritoneal fixation technique to standard of care (no fixation) during robot-assisted radical prostatectomy with extended pelvic lymph node dissection (RARP + eLND) for the prevention of symptomatic and radiologic lymphocele formation.

Detailed description

Extended pelvic lymph node dissection (ePLND) is the most accurate staging tool to determine lymph node involvement in prostate cancer. As urologist perform this procedure more often now, thanks to the shift to more advanced and aggressive stages, the role of ePLND is expanding. The main complication of PLND is development of a collection of lymphatic fluid called a lymphocele. Lymphoceles can be associated with abdominal pain, lower urinary tract symptoms, bladder outlet obstruction, penile or scrotal edema, infection/sepsis, lower extremity swelling and deep vein thrombosis. They necessitate intervention in up to 10% of patients treated with RARP + ePLND which includes drainage or surgery. Radiologic incidence can be as high as around 50% of operated patients with unknown clinical relevance. Many interventions aimed at reducing the rate of lymphocele formation with limited success so far. Several retrospective studies suggested using peritoneal flap fixation technique which could direct the lymphatic fluid to the peritoneal cavity out of the pelvis and its ensure its reabsorption there. We hypothesize that peritoneal fixation can potentially lower the incidence of symptomatic and radiologic lymphocele formation. By preventing this potentially very dangerous complication, it could be very beneficial for a large group of patients suffering from aggressive localized prostate cancer who are scheduled for RARP + ePLND. Our goal is to is to test this hypothesis in a randomized trial comparing the fixation technique to standard of care, i.e. no fixation.

Interventions

PROCEDUREPeritoneal fixation (PerFix)

PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.

PROCEDUREStandard of care

ePLND without peritoneal flap fixation

Sponsors

University Hospital Olomouc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Able to give informed consent * Histologically proven high risk prostate cancer or intermediate risk cancer (≥5% risk of nodal involvement on Briganti 2012 nomogram) according to European Association od Urology (EAU) risk groups * Suitable for minimally-invasive surgery

Exclusion criteria

* Previous pelvic surgery or irradiation. * Any type of clotting disorder. * Patients unwilling to undergo CT scan * Kidney failure, Hemodialysis * American Society of Anesthesiology Classification\> 3 * Existing contraindications for performing a lymph node dissection

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with Symptomatic lymphocele3 monthsThe number of participants with symptomatic lymphocele will be determined. Clinical symptoms, time of onset, the size of the lymphocele, location, number of Lymphoceles and intervention needed will be measured

Secondary

MeasureTime frameDescription
Rate of severe (Clavien grade ≥3) complications3 monthsIncidence of adverse events in the Prefix group compared to control group (no PerFix) will be measured. Surgical complications will be evaluated according to Clavien-Dindo classification
Change in lymphocele size1 yearThe change in lymphocele size during follow-up CT scan will be examined
Number of participants with Occurrence of Any Venous Thromboembolism6 monthsRadiologic investigation will be done in case of by swelling or pain of the lower extremity and the number of any venous thromboembolism will be determined
Number of participants with Radiologic lymphocele on pelvic CT scan3 monthsThe number of participants with radiologic lymphocele on Pelvic CT scan will be determined together with the size, location and number of detected lymphoceles.
The effect of lymphocele on urinary incontinence1 yearThe rate of continent patients will be defined using pads needed per day. Continent equals to 0-1 pad per day.
The effect of lymphocele on potency1 yearPotency equals to 19 and more points in the International index of erectile function (IIEF5) questionnaire (scale 0-25), the higher the score, the better.
The effect of lymphocele on lower urinary tract symptoms (LUTS)1 yearChange in the International prostate symptom score (IPSS) questionnaire from the baseline will be assessed (scale 0-35, higher score means worse outcome).
Perioperative outcomes30 daysPerioperative outcomes (time of the surgery, blood loss and hospital stay) will be measured

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026